Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
Portfolio Pulse from Benzinga Insights
Legend Biotech (NASDAQ:LEGN) has received mixed analyst ratings over the past three months, with a total of 14 analysts offering their perspectives. The ratings include 8 bullish, 6 somewhat bullish, and no bearish views. The 12-month price targets suggest an average of $84.07, with a high of $87.00 and a low of $65.00, marking a 10.62% increase from the previous average of $76.00. The company's financial health shows significant revenue growth but challenges in profitability and asset utilization.
May 14, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Legend Biotech has seen a positive shift in analyst ratings and price targets, indicating a bullish sentiment among analysts. The company's significant revenue growth is a strong point, although profitability and asset utilization pose challenges.
The increase in bullish ratings and the upward revision of price targets suggest a positive outlook for LEGN, likely to influence investor sentiment positively. However, the concerns regarding profitability and asset utilization may temper the enthusiasm to some extent.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100